Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
HM03 (HM-03) is a novel, potent and selective HSPA5 (also known as Heat shock 70kDa protein 5, Bip, Grp78) inhibitor with anticancer activity.
Targets |
HSPA5
|
---|---|
ln Vitro |
At a binding concentration of 25 μM, HM03 (0.1-50 μM; 72 hours) shows over 50% inhibition in HCT116 cells [1]. When combined with HSPA5 and HSPA9, HM03 forms more sensitive cells than other HSP70 proteins.
|
Cell Assay |
Cell Viability Assay[1]
Cell Types: HCT116 cells Tested Concentrations: 0.1, 1, 10, 25, 50 μM Incubation Time [1]. Incubation Duration: 72 hrs (hours) Experimental Results: Demonstrated significant inhibitory effect (18% survival rate at 25 µM). |
References |
[1]. Huang M, et al. Structure-based design of HSPA5 inhibitors: from peptide to small molecule inhibitors. Bioorg Med Chem Lett. 2013;23(10):3044‐3050.
|
Molecular Formula |
C26H27CLN4O2
|
---|---|
Molecular Weight |
471.2098
|
Exact Mass |
462.18
|
Elemental Analysis |
C, 67.45; H, 5.88; Cl, 7.66; N, 12.10; O, 6.91
|
CAS # |
500565-15-1
|
Related CAS # |
HM03 trihydrochloride;1082532-95-3
|
Appearance |
Solid powder
|
SMILES |
CN1CCN(CC1)CC2=C(C=CC(=C2)NC3=C4C=C(C=CC4=NC5=C3C=CC(=C5)Cl)OC)O
|
InChi Key |
SUSDGTMJKOGWSZ-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C26H27ClN4O2/c1-30-9-11-31(12-10-30)16-17-13-19(4-8-25(17)32)28-26-21-6-3-18(27)14-24(21)29-23-7-5-20(33-2)15-22(23)26/h3-8,13-15,32H,9-12,16H2,1-2H3,(H,28,29)
|
Chemical Name |
4-[(6-chloro-2-methoxyacridin-9-yl)amino]-2-[(4-methylpiperazin-1-yl)methyl]phenol
|
Synonyms |
HM03; HM-03; HM 03; F06; NSC130813; NSC-130813; NSC 130813
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~125 mg/mL (~270.0 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (13.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1222 mL | 10.6110 mL | 21.2220 mL | |
5 mM | 0.4244 mL | 2.1222 mL | 4.2444 mL | |
10 mM | 0.2122 mL | 1.0611 mL | 2.1222 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.